137 related articles for article (PubMed ID: 37555785)
21. Prediction models for prostate cancer to be used in the primary care setting: a systematic review.
Aladwani M; Lophatananon A; Ollier W; Muir K
BMJ Open; 2020 Jul; 10(7):e034661. PubMed ID: 32690501
[TBL] [Abstract][Full Text] [Related]
22. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
23. Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.
Campi R; Brookman-May SD; Subiela Henríquez JD; Akdoğan B; Brausi M; Klatte T; Langenhuijsen JF; Linares-Espinos E; Marszalek M; Roupret M; Stief CG; Volpe A; Minervini A; Rodriguez-Faba O
Eur Urol Focus; 2019 Nov; 5(6):1029-1057. PubMed ID: 29661588
[TBL] [Abstract][Full Text] [Related]
24. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of the main PSA glycoforms in aggressive prostate cancer.
Gratacós-Mulleras A; Duran A; Asadi Shehni A; Ferrer-Batallé M; Ramírez M; Comet J; de Llorens R; Saldova R; Llop E; Peracaula R
Sci Rep; 2020 Nov; 10(1):18974. PubMed ID: 33149259
[TBL] [Abstract][Full Text] [Related]
26. Relative contribution of digital rectal examination and transrectal ultrasonography in interpreting serum prostate-specific antigen values for screening prostate cancer in Arab men.
Sheikh M; Sinan T; Kehinde EO; Hussein AY; Anim JT; Al-Hunayan AA
Ann Saudi Med; 2007; 27(2):73-8. PubMed ID: 17356323
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
28. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
29. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
30. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
31. PSA screening: a public health dilemma.
Mandelson MT; Wagner EH; Thompson RS
Annu Rev Public Health; 1995; 16():283-306. PubMed ID: 7543756
[TBL] [Abstract][Full Text] [Related]
32. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
Segal N; Ber Y; Benjaminov O; Tamir S; Yakimov M; Kedar I; Rosenbaum E; Sela S; Ozalvo R; Shavit-Grievink L; Keder D; Baniel J; Margel D
Ann Oncol; 2020 Nov; 31(11):1545-1552. PubMed ID: 32958357
[TBL] [Abstract][Full Text] [Related]
33. Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
Chung JH; Yu J; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
J Korean Med Sci; 2020 Oct; 35(41):e342. PubMed ID: 33107227
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.
Joniau S; Spahn M; Briganti A; Gandaglia G; Tombal B; Tosco L; Marchioro G; Hsu CY; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; van Poppel H; Gontero P;
Eur Urol; 2015 Feb; 67(2):319-25. PubMed ID: 24684960
[TBL] [Abstract][Full Text] [Related]
35. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
[TBL] [Abstract][Full Text] [Related]
36. Changes in serum PSA after endoscopic enucleation of the prostate are predictive for the future diagnosis of prostate cancer.
Lambert E; Goossens M; Palagonia E; Vollemaere J; Mazzone E; Dell'Oglio P; Pauwels E; De Groote R; D'Hondt F; Mottrie A; De Naeyer G; Schatteman P
World J Urol; 2021 Jul; 39(7):2621-2626. PubMed ID: 32997261
[TBL] [Abstract][Full Text] [Related]
37. Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.
Heidegger I; Fritz J; Klocker H; Pichler R; Bektic J; Horninger W
PLoS One; 2015; 10(7):e0134134. PubMed ID: 26218594
[TBL] [Abstract][Full Text] [Related]
38. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
[TBL] [Abstract][Full Text] [Related]
40. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
